756525-95-8

Basic information

• Product Name: H2N-PEG2-tBu
• Synonyms: H2N-PEG2-tBu;tert-Butyl 9-AMino-4,7-dioxanonanoate (H2N-PEG2-tBu) tert-butyl 9-AMino-4,7-dioxanonanoate;3-[2-(2-Aminoethoxy)ethoxy]propanoic acid 1,1-dimethylethyl ester;H2N-PEG2-CH2CH2COOtBu;Amino-PEG2-t-butyl ester;Amino-PEG3-t-butyl ester;H2N-PEG2-CH2CH2COOtBu;Amino-PEG2-acid -t-Butyl ester
• CAS NO: 756525-95-8
• Molecular Formula: C₁₁H₂₃NO₄
• Molecular Weight: 233.30462
• Product Categories: PEG-COOtBu
• Mol File: 756525-95-8.mol

Chemical Properties

• Boiling Point: 313.7±22.0 °C(Predicted)
• Appearance: /
• Density: 1.014±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 8.74±0.10(Predicted)
• CAS DataBase Reference: H2N-PEG2-tBu(CAS DataBase Reference)
• NIST Chemistry Reference: H2N-PEG2-tBu(756525-95-8)
• EPA Substance Registry System: H2N-PEG2-tBu(756525-95-8)

Safety Data

• Hazardous Substances Data: 756525-95-8(Hazardous Substances Data)

Usage

Uses

Used in Bioconjugation and Chemical Synthesis:
H2N-PEG2-tBu is used as a PEG linker for the synthesis of self-localizing ligands that control the spatial location of proteins in living cells. Its reactivity with different functional groups and the ability to deprotect the carboxyl group under acidic conditions make it a valuable component in the development of targeted drug delivery systems and bioconjugation strategies.
Used in Drug Delivery Systems:
In the pharmaceutical industry, H2N-PEG2-tBu is used as a key component in the design of drug delivery systems. Its PEGylation properties can improve the solubility, stability, and bioavailability of therapeutic agents, while its reactive amino group allows for the attachment of various drug molecules or targeting ligands. This enables the development of more effective and targeted treatments with reduced side effects.
Used in Protein Engineering:
In the field of protein engineering, H2N-PEG2-tBu is utilized as a building block for the creation of protein conjugates with enhanced properties. The PEG linker can be used to attach functional moieties, such as fluorescent tags or therapeutic agents, to proteins, enabling the development of novel protein-based therapies and diagnostic tools.
Used in Nanotechnology:
H2N-PEG2-tBu is also employed in nanotechnology applications, where it serves as a stabilizing and functionalizing agent for the synthesis of nanoparticles. The PEG linker can be used to modify the surface properties of nanoparticles, enhancing their biocompatibility, circulation time, and targeting capabilities, which are crucial for applications in drug delivery, imaging, and diagnostics.

Upstream product

• 133803-81-3 2-methyl-2-propanyl 3-[2-(2-hydroxyethoxy)ethoxy]propanoate 
• 850090-13-0 9-(p-toluenesulfonyloxy)-3,6-diocanonanoic acid tert-butyl ester 
• 1629676-51-2 C₁₉H₂₅NO₆ 
• 1629676-61-4 3-(2-(2-(2-(dibenzylamino)ethoxy)ethoxy))tert-butyl propionate 
• 1663-39-4 tert-Butyl acrylate 
• 1271728-79-0 tert-butyl 3-(2-(2-azidoethoxy)ethoxy)propanoate 
• 1938057-43-2 tert-butyl 3-(2-(2-iodoethoxy)ethoxy)propanoate 

Downstream Products

• 1037589-69-7 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-{2-[2-(3-oxo-3-{4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]phenylamino}propoxy)ethoxy]ethyl}propanamide 
• 1374677-38-9 C₃₀H₄₇N₅O₁₃S 
• 1374666-25-7 C₂₇H₃₄N₄O₈ 
• 1374666-27-9 C₂₄H₂₉N₃O₇ 
• 756525-98-1 3-(2-{2-[3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido]ethoxy}ethoxy)propanoic acid 
• 1374666-26-8 C₁₂H₁₇NO₆ 
• 1449685-11-3 C₂₉H₄₅N₅O₈ 
• 1449685-12-4 C₂₅H₃₇N₅O₈ 
• 1449685-13-5 C₂₈H₄₃N₉O₇ 
• 1620172-07-7 C₉₂H₁₆₀N₁₄O₂₀ 

Relevant articles and documents

TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to a target protein degradation-inducing Degraducer, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases related to EED, EZH2, or PRC2 comprising same as an active ingredient. A novel compound represented by formula 1, according to the present invention is a Degraducer compound that induces degradation of a target protein, i.e., embryonic ectoderm development (EED) or polycomb repressive complex 2 (PRC2), utilizing cereblon E3 ubiquitin ligase, von Hippel-Lindau tumor suppressor (VHL) E3 ubiquitin ligase, mouse double minute 2 homolog (MDM2) E3 ubiquitin ligase, and cellular inhibitor of apoptosis protein 1 (cIAP) E3 ubiquitin ligase, wherein the compound has an aspect of remarkably achieving target protein degradation-inducing activity through a ubiquitin proteasome system (UPS), and therefore there is a useful effect in that it is possible to provide a pharmaceutical composition for preventing or treating diseases or conditions related to a target protein, and a functional health food composition for preventing or improving same, comprising said compound as an active ingredient.

CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES

A novel cross-linked cytotoxic agents, pyrrolobenzo-diazepine dimer (PBD) derivatives, and their conjugates to a cell-binding molecule, a method for preparation of the conjugates and the therapeutic use of the conjugates.

CONJUGATION LINKERS CONTAINING 2,3-DIAMINOSUCCINYL GROUP

Provided is a conjugate of a cytotoxic drug/molecule to a cell-binding molecule with a bis-linker (adual-linker) containing a 2, 3-diaminosuccinyl group. It also relates to preparation of the conjugate of a cytotoxic drug/molecule to a cell-binding molecule with the bis-linker, particularly when the drug having functional groups of amino, hydroxyl, diamino, amino-hydroxyl, dihydroxyl, carboxyl, hydrazine, aldehyde and thiol for conjugation with the bis-linker in a specific manner, as well as the therapeutic use of the conjugates.

A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS

The present invention relates to the conjugation of a tubulysin analog compound to a cell-binding molecule with branched/side-chain linkers for having better delivery of the conjugate compound and targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of a tubulysin analog molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and autoimmune disease.

Identification of New Small-Molecule Inducers of Estrogen-related Receptor α (ERRα) Degradation

A series of (E)-3-(4-((2,4-bis(trifluoromethyl)benzyl)oxy)-3-methoxyphenyl)-2-cyanoacrylamide derivatives were designed and synthesized as new estrogen-related receptor α (ERRα) degraders based on the proteolysis targeting chimera (PROTAC) concept. One of the representative compounds 6c is capable of specifically degrading ERRα protein by >80% at a relatively low concentration of 30 nM, becoming one of the most potent and selective ERRα degraders to date. Compound 6c could be utilized as a new powerful research tool for further biological investigation of ERRα.

CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE

What provided is the conjugation of cytotoxic to a cell-binding molecule with a bis-linker(dual-linker) as shown in Formula (I). It provides bis-linkage methods of making a conjugate of a cytotoxic drug molecule to a cell-binding agent in a specific manner. It also relates to application of the conjugates for the treatment of a cancer, or an autoimmune disease, or an infectious disease.

A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS

The present invention relates to the conjugation of a tubulysin analog compound to a cell-binding molecule with branched/side-chain linkers for having better delivery of the conjugate compound and targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of a tubulysin analog molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and autoimmune disease.

CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LIKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS

The present invention relates to linkers having a group of propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl, and using such linkers for the conjugation of compounds, in particular, cytotoxic agents to a cell-binding molecule.

Heat stabilizer for PVC and synthesizing method of heat stabilizer

The invention provides a novel metallic soap heat stabilizer. The novel metallic soap heat stabilizer structurally comprises maleimide groups, substituted amide groups, multi-ether groups and metal ions and can be used as the heat stabilizer in a PVC proc

DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULE

Derivatives of Amernita toxins of Formula (I), wherein, formula (a) R 1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, R 9, R 10, X, L, m, n and Q are defined herein. The preparation of the derivatives. The therapeutic use of the derivatives in the targeted treatment of cancers, autoimmune disorders, and infectious diseases.